Allergan Rises On Unusually High Volume (AGN)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Allergan (NYSE: AGN) is trading at unusually high volume Tuesday with 4.5 million shares changing hands. It is currently at two times its average daily volume and trading up $2.34 (+2.9%) at $84.33 as of 12:15 p.m. ET.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Allergan has a market cap of $27.48 billion and is part of the health care sector and drugs industry. Shares are down 10.6% year to date as of the close of trading on Monday.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company has a P/E ratio of 24.9, above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full Allergan Ratings Report.

See all heavy volume stocks in our stocks moving on unusual volume list or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Centene: Cramer's Top Takeaways

The Pitney Bowes Transformation: Cramer's Top Takeaways

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)